Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

February 22, 2023

Multi-Specific Monoclonal
The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralise or promote its activity. The efficacy and safety.

Spotlight

BiOZEEN

BiOZEEN provides robust automated bioprocess technologies to enable the biopharmaceutical industry manufacture regulatory compliant and economically competitive vaccines and biologicals. Our deep expertise and experience in Bioprocess Engineering, Plant Automation, Fabrication Technologies and User Philosophies allow us to synthesise customised bioprocess hardware and automation infrastructure for enhanced productivity.

OTHER WHITEPAPERS
news image

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More
news image

Valorization of Starch to Biobased Materials

whitePaper | May 30, 2022

Many concerns are being expressed about the biodegradability, biocompatibility, and longterm viability of polymer-based substances. This prompted the quest for an alternative source of material that could be utilized for various purposes.

Read More
news image

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

Read More
news image

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Read More
news image

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

whitePaper | December 22, 2022

Determining the physical titer of viral vectors has typically been accomplished using digital droplet PCR (ddPCR). Droplet-based methods, however, are challenged by matrix effects and long analysis times (up to 7 hours).

Read More
news image

Gene and cell therapy analytical and development methods

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.

Read More

Spotlight

BiOZEEN

BiOZEEN provides robust automated bioprocess technologies to enable the biopharmaceutical industry manufacture regulatory compliant and economically competitive vaccines and biologicals. Our deep expertise and experience in Bioprocess Engineering, Plant Automation, Fabrication Technologies and User Philosophies allow us to synthesise customised bioprocess hardware and automation infrastructure for enhanced productivity.

Events